Cuong Do, MBA, is the President and Chief Executive Officer of BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. Do is a highly experienced life sciences executive, who has served in various leadership roles at multiple global enterprises and publicly owned companies over the past 35 years. Prior to his appointment with BioVie, Do was President of Samsung Global Strategy Group where he helped to set the strategic direction for the company’s diverse business portfolio, including the growth of its biologics businesses. He was previously the Chief Strategy Officer for Merck, a leading US pharmaceutical company on the Fortune 500 list, where he played a key role in defining the company’s strategy, including its focus on oncology and creating its leading position with the anti-PD-1 therapy, pembrolizumab (KEYTRUDA®).
Do also held leadership roles in the technology space at Lenovo and Tyco Electronics, and was a senior partner at McKinsey & Company, where he spent 17 years helping to build the company’s healthcare, high tech and corporate finance practices.
Do is an active entrepreneur who founded Callidus Biopharma (a biotech company working in rare diseases that was acquired by Amicus Therapeutics in 2013), Lysodel Therapeutics (a company developing an innovative pharmaceutical product for obesity), and M6P Therapeutics (a company developing gene and enzyme replacement therapies for rare lysosomal storage disorders).
He is a founding member of Social Impact Partners, which is a purpose-driven alliance of global experts and young change-makers working to fight against Alzheimer’s Disease. Do also serves as a member of multiple advisory boards to companies and academic institutions, including Seneca Therapeutics, Stanford Medicine, The Tuck School of Business at Dartmouth, Fulbright University Vietnam, Ideal Semiconductors, ILiAD Biotechnologies and others.
Do is also a passionate philanthropist, particularly in autism and education. He founded Profectum Foundation, which specializes in providing training and education for professionals and parents of children with autism or special needs. He also founded Identifor, Inc. and the Identifor Foundation to help autistic teenagers identify abilities and strengths to make the transition to adulthood. He currently or formerly served on the boards of Celebrate the Children (a school for children with special needs in New Jersey), Autism Speaks and its Executive, Strategy, Science and Family Services committees and Caring for Cambodia (a non-profit working to educate 7,000+ K-12 students in Siem Reap, Cambodia).
What is Cuong V. Do's net worth?
The estimated net worth of Cuong V. Do is at least $23.64 thousand as of August 27th, 2026. Mr. Do owns 16,117 shares of BioVie stock worth more than $23,644 as of October 6th. This net worth approximation does not reflect any other investments that Mr. Do may own. Learn More about Cuong V. Do's net worth.
How do I contact Cuong V. Do?
Has Cuong V. Do been buying or selling shares of BioVie?
Cuong V. Do has not been actively trading shares of BioVie during the past quarter. Most recently, on Thursday, August 27th, Cuong V. Do bought 15,210 shares of BioVie stock. The stock was acquired at an average cost of $2.08 per share, with a total value of $31,636.80. Following the completion of the transaction, the chief executive officer now directly owns 16,117 shares of the company's stock, valued at $33,523.36. Learn More on Cuong V. Do's trading history.
Who are BioVie's active insiders?
Are insiders buying or selling shares of BioVie?
During the last twelve months, BioVie insiders bought shares 4 times. They purchased a total of 23,280 shares worth more than $49,118.00. The most recent insider tranaction occured on August, 28th when insider Joseph M Palumbo bought 4,843 shares worth more than $10,460.88. Insiders at BioVie own 0.9% of the company.
Learn More about insider trades at BioVie. Information on this page was last updated on 8/28/2026.
